N-(4-(imidazo[1,2-a]pyridin-3-yl)phenyl)-5-nitrofuran-2-carboxamide

ID: ALA5278396

Max Phase: Preclinical

Molecular Formula: C18H12N4O4

Molecular Weight: 348.32

Names and Identifiers

Canonical SMILES:  O=C(Nc1ccc(-c2cnc3ccccn23)cc1)c1ccc([N+](=O)[O-])o1

Standard InChI:  InChI=1S/C18H12N4O4/c23-18(15-8-9-17(26-15)22(24)25)20-13-6-4-12(5-7-13)14-11-19-16-3-1-2-10-21(14)16/h1-11H,(H,20,23)

Standard InChI Key:  OEFICDBZRUDUCL-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 29  0  0  0  0  0  0  0  0999 V2000
   -3.2484   -0.2936    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9930    0.4908    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -3.5468    1.1056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.3596    0.9327    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.6102    0.1446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -4.0580   -0.4659    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -3.1330    1.8224    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3236    1.6503    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.2371    0.8273    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5201    0.4134    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.5201   -0.4177    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8014   -0.8271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0890   -0.4140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.6274   -0.8276    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.3439   -0.4140    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.3439    0.4133    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.0604   -0.8276    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1469   -1.6501    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9558   -1.8220    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.3692   -1.1059    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.1967   -1.1059    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6102   -0.3894    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    4.6102   -1.8224    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    2.8159   -0.4913    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   -0.0890    0.4138    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8032    0.8271    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  2  3  1  0
  3  4  1  0
  4  5  2  0
  6  1  2  0
  5  6  1  0
  3  7  2  0
  7  8  1  0
  8  9  2  0
  9  2  1  0
  9 10  1  0
 10 11  1  0
 11 12  2  0
 12 13  1  0
 13 14  1  0
 14 15  1  0
 15 16  2  0
 15 17  1  0
 18 17  2  0
 19 18  1  0
 20 19  2  0
 21 20  1  0
 21 22  2  0
 21 23  1  0
 24 20  1  0
 24 17  1  0
 13 25  2  0
 25 26  1  0
 26 10  2  0
M  CHG  2  21   1  23  -1
M  END

Alternative Forms

1. Parent:

   

   ALA5278396

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 348.32

Molecular Weight (Monoisotopic): 348.0859

AlogP: 3.75

#Rotatable Bonds: 4

Polar Surface Area: 102.68

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 8

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 12.62

CX Basic pKa: 5.98

CX LogP: 2.51

CX LogD: 2.49

Aromatic Rings: 4

Heavy Atoms: 26

QED Weighted: 0.45

Np Likeness Score: -2.22

References

1. Li H, Ouyang S, Zhang Y, Peng K, Fang W, Liu Z, Wang CY, Zhang X, Wang Y..  (2022)  Structural optimization of Imidazo[1, 2-a]pyridine derivatives for the treatment of gastric cancer via STAT3 signaling pathway.,  244  [PMID:36283181] [10.1016/j.ejmech.2022.114858]

Source

Source(1):

• Scientific Literature